Royalty Pharma PLC

Royalty Pharma PLC, a finance company headquartered in New York, acquires royalty interests in pharmaceutical products. This business model allows it to generate revenue from the sales of drugs developed and marketed by other pharmaceutical and biotechnology companies. Instead of engaging in drug discovery, development, or manufacturing itself, Royalty Pharma provides capital to drug developers in exchange for a percentage of future sales of their approved therapies. This strategy positions the company to benefit from the success of a diverse portfolio of established and pipeline pharmaceutical products without incurring the significant research and development costs associated with bringing new drugs to market.

The company's operations involve purchasing existing royalty streams from universities, research institutions, and small to mid-sized biotech firms, as well as providing funding directly to pharmaceutical companies in exchange for future royalties on their products. This focus on financing and intellectual property rights rather than drug production defines its place within the finance industry. Pablo Legorreta's wealth is directly linked to the performance and value of Royalty Pharma, reflecting his significant stake in the company.